The commutability of enzyme linked immunosorbent assays for the quantification of serum eosinophil-derived neurotoxin (EDN).


Journal

Journal of immunological methods
ISSN: 1872-7905
Titre abrégé: J Immunol Methods
Pays: Netherlands
ID NLM: 1305440

Informations de publication

Date de publication:
01 2022
Historique:
received: 22 08 2021
revised: 28 10 2021
accepted: 03 11 2021
pubmed: 12 11 2021
medline: 7 1 2022
entrez: 11 11 2021
Statut: ppublish

Résumé

Eosinophil-derived neurotoxin (EDN) is a surrogate biomarker of eosinophil activation and has considerable potential as a precision medicine biomarker in diseases where eosinophils may play a causative role. Clinical data for EDN have been generated using different quantitative immunoassays, but comparisons between these individual data sets are challenging as no internationally recognised EDN standards or orthogonal methods exist. In this study we aimed to compare commercial EDN assays from ALPCO, MBL, LSBio and CUSABIO for sample commutability. Firstly, we analytically validated the ALPCO enzyme linked immunosorbent assay (ELISA) and demonstrated appropriate analytical characteristics, including an intra/inter-assay precision coefficient-of-variation of between 1.9 and 6.8%. EDN purified from blood proved to be a good quality control material, whereas recombinant EDN, expressed in E.coli, did not react in the ALPCO immunoassay. Using healthy and asthma patient serum samples we confirmed that the ALPCO assay correlated well with the MBL assay, with a coefficient of determination (R

Identifiants

pubmed: 34762913
pii: S0022-1759(21)00226-X
doi: 10.1016/j.jim.2021.113181
pii:
doi:

Substances chimiques

Biomarkers 0
Eosinophil-Derived Neurotoxin EC 3.1.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

113181

Informations de copyright

Copyright © 2021. Published by Elsevier B.V.

Auteurs

Bert Rutten (B)

Precision Medicine, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.

Simon Young (S)

Research and Development Centre, Sysmex, Cambridge, United Kingdom.

Sarah Aldridge (S)

Precision Medicine, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.

Rick Davies (R)

Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.

Mark Fidock (M)

Precision Medicine, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.

Paul Newbold (P)

Late Stage Respiratory and Immunology, Biopharmaceutical R&D, AstraZeneca, Gaithersburg, MD, United States.

Dave Singh (D)

Medicines Evaluation Unit, University of Manchester, Manchester University NHS Foundation Hospital Trust, Manchester, United Kingdom.

Adam Platt (A)

Translational Science and Experimental Medicine, Research and Early Development, Respiratory & Immunology, Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.

Glen Hughes (G)

Precision Medicine, Oncology R&D, AstraZeneca, Cambridge, United Kingdom. Electronic address: glen.hughes@astrazeneca.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH